Section Arrow
HALO.NASDAQ
- Halozyme Therapeutics
Quotes are at least 15-min delayed:2026/05/22 17:30 EDT
After Hours
Last
 69.0246
+0.7046 (+1.03%)
Bid
67.3
Ask
69.3
High 69.0246 
Low 67.56 
Volume 114.48K 
Regular Hours (Closed)
Last
 68.32
-0.2 (-0.29%)
Day High 
68.845 
Prev. Close
68.52 
1-M High
73.89 
Volume 
1.20M 
Bid
67.3
Ask
69.3
Day Low
67.83 
Open
68.52 
1-M Low
62.38 
Market Cap 
8.13B 
Currency 美元 
P/E 23.97 
%Yield -- 
10-SMA 68.15 
20-SMA 66.39 
50-SMA 65.66 
52-W High 82.22 
52-W Low 51.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.85/9.89
Enterprise Value
10.27B
Balance Sheet
Book Value Per Share
1.85
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
1.40B
Operating Revenue Per Share
6.58
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
After Hours 3.63 -0.01 -0.27%
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
After Hours 3.55 -0.3 -7.79%
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
After Hours 13.61 -4.66 -25.51%
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
After Hours 0.163 -0.0064 -3.78%
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
After Hours 4.09 -0.02 -0.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.